Asset
LUMASIRAN SODIUM
Alnylam Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (0)
No records yet.
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 214103 | NDA | ALNYLAM PHARMACEUTICALS INC |
Marketed products (1)
- OXLUMO